Full Press Release Details
CRISPR Therapeutics and Vertex Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022.
CRSP
CRISPR Therapeutics and Vertex Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
Key Takeaway: CRISPR Therapeutics and Vertex Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
Price reaction · baseline $61.1 (2022-09-26 close) · hit after-hours · 2 other CRSP headline(s) in the window, move may be shared
day 0 close · peak
+4.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.4%
average across 2 past catalysts
Cash runway
~84 mo
Minimal dilution risk
Lead asset
CTX340
Phase 1 · Hypertension